C2 PHARMA AND THERACULE ANNOUNCE STRATEGIC PARTNERSHIP
- C2 PHARMA leads seed funding of Theracule AS
- Theracule AS is an orphan drug development company focused on rare
neurological disorders
Luxembourg and Oslo, October 4, 2018 – C2 PHARMA (Hall 6, Booth 6F40)
and Theracule AS are entering into a strategic partnership focused on supporting
Theracule’s new drug development programs aimed at rare neurodevelopmental
disorders. The programs are based on a plant-derived API and a botanical extract
which C2 PHARMA is having manufactured for Theracule.
In addition to supporting the manufacturing of the botanical extract for Theracule,
C2 PHARMA is leading the seed funding that will finance the company’s operations
for the next 12-18 months. Theracule will raise its Series A funding supported by
key milestones expected to be achieved during this timeframe.
“The partnership with C2 PHARMA goes beyond the financial support that a
typical seed round investor would deliver,” said Dr. Ana Mingorance,
co-founder of Theracule. “We also get best GMP-compliant botanical extracts
and APIs, regulatory support, analytical sciences support through ASM
Research Chemicals, and the backing of one of the leading API companies in
the phytochemical field.”
Andrew Badrot, CEO of C2 PHARMA, added: “We are excited to work with
Theracule and help them develop a new botanical extract and plant-
derived APIs to treat rare diseases. Theracule’s funding team have a wealth of
expertise in new drug development for rare neurological disorders. With
C2 PHARMA’s manufacturing and technical capabilities, we have a ‘dream team’
that will deliver outstanding results.”